Home » Stocks » PRVL

Prevail Therapeutics Inc. (PRVL)

Stock Price: $23.00 USD -0.02 (-0.09%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 787.70M
Revenue (ttm) n/a
Net Income (ttm) -77.10M
Shares Out 33.64M
EPS (ttm) -2.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $23.00
Previous Close $23.02
Change ($) -0.02
Change (%) -0.09%
Day's Open -
Day's Range 22.97 - 23.13
Day's Volume 0
52-Week Range 9.33 - 23.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 days ago

INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acqui...

Other stocks mentioned: LLY
Seeking Alpha - 3 days ago

Prevail getting bought by Eli Lilly for $22.50 plus a potential $4.00 in CVR payments. The payment terms are straightforward and the timeline is long here, which improves the chances of the CV...

PRNewsWire - 1 month ago

SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Prevail Therapeutics Inc. ("Prevail" or...

PRNewsWire - 1 month ago

NEW YORK, Dec. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...

GlobeNewsWire - 1 month ago

WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breache...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pr...

Zacks Investment Research - 1 month ago

Lilly (LLY) inks a deal to acquire Prevail Therapeutics for an upfront payment of $880 million, which will add gene therapy programs to its pipeline.

Other stocks mentioned: LLY
GuruFocus - 1 month ago

On Tuesday morning, drugmaker Eli Lilly & Co. (NYSE:LLY) announced that it plans to purchase Prevail Therapeutics Inc. (NASDAQ:PRVL), a gene therapy developer, in an all-cash deal that values ...

Other stocks mentioned: LLY
PRNewsWire - 1 month ago

NEW YORK, Dec. 15, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prevail Therapeutics Inc. ("P...

The Motley Fool - 1 month ago

The buyer is also on the hook for a milestone payment that could hit $4 per share.

Other stocks mentioned: LLY
Invezz - 1 month ago

Eli Lilly & Co. (NYSE: LLY) expressed plans of acquiring Prevail Therapeutics Inc. (NASDAQ: PRVL) on Tuesday for £770 million – a move that it says will help it expand its footprint in gene th...

Other stocks mentioned: LLY
Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Prevail Therapeutics Inc. (NASDAQ: PRVL) to Eli Lilly and Company is fair t...

The Motley Fool - 1 month ago

Stocks were higher in general as investors remained optimistic about the future.

Other stocks mentioned: PLUG
The Motley Fool - 1 month ago

Lilly announced plans to acquire the small biotech.

Other stocks mentioned: LLY
Investors Business Daily - 1 month ago

Eli Lilly agreed to buy gene therapy company Prevail Therapeutics for $1.04 billion on Tuesday, sending PRVL stock to a record high. The deal is worth $880 million up front and a CVR.

Other stocks mentioned: LLY
Benzinga - 1 month ago

Eli Lilly And Co (NYSE: LLY) announced Tuesday a big-ticket acquisition that would mark its foray into gene therapy research. What Happened: Lilly said it has agreed to buy gene therapy compan...

Other stocks mentioned: LLY
InvestorPlace - 1 month ago

Prevail Therapeutics (PRVL) stock is soaring higher on Tuesday following news of a massive $880 million deal with Eli Lilly (LLY). The post PRVL Stock: Why Gene Therapy Play Prevail Therapeuti...

Other stocks mentioned: LLY
24/7 Wall Street - 1 month ago

Prevail Therapeutics Inc. (NASDAQ: PRVL) shares absolutely exploded on Tuesday morning after it was announced that the company would be acquired by Eli Lilly and Co.

Other stocks mentioned: LLY
Schaeffers Research - 1 month ago

The shares of Eli Lilly And Co (NYSE:LLY) are up 1.9% at $160.83 at last check, after the pharmaceutical giant said it would buy Prevail Therapeutics (PRVL) for $1.04 billion, in an effort to ...

Other stocks mentioned: LLY
Business Insider - 1 month ago

Prevail Therapeutics soared as much as 86% in early Tuesday trading after pharmaceutical giant Eli Lilly announced plans to purchase the gene therapy firm. The deal leaves Eli Lilly to pay $22...

Other stocks mentioned: LLY
Reuters - 1 month ago

(Reuters) -Eli Lilly and Co said on Tuesday it would buy Prevail Therapeutics Inc in a deal potentially valued at $1.04 billion, to expand its presence in the lucrative field of gene therapy.

Other stocks mentioned: LLY
Market Watch - 1 month ago

Shares of Prevail Therapeutics Inc. nearly rocketed 98.3% in premarket trading Tuesday, after the gene therapy company agreed to be acquired by Eli Lilly & Co. in a deal with a total value of ...

Other stocks mentioned: LLY
PRNewsWire - 1 month ago

INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acqu...

Other stocks mentioned: LLY
GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients wit...

GlobeNewsWire - 1 month ago

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients wit...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients wit...

GlobeNewsWire - 2 months ago

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson's Disease with GBA1 Mutations

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients wit...

GlobeNewsWire - 2 months ago

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients wit...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients ...

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patient...

Seeking Alpha - 5 months ago

Prevail Therapeutics Inc.'s (PRVL) CEO Asa Abeliovich on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Preliminary Data Demonstrates Normalization of CSF GBA1 Enzyme Activity in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease Patients

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...

GlobeNewsWire - 5 months ago

Gene Therapy is Being Developed for the Treatment of Frontotemporal Dementia patients with GRN Mutations Gene Therapy is Being Developed for the Treatment of Frontotemporal Dementia patients w...

Benzinga - 6 months ago

Prevail Therapeutics (NASDAQ: PRVL) shares are trading higher on Thursday after the company reported it will highlight multiple gene therapy programs for neurodegenerative diseases at the 2020...

GlobeNewsWire - 6 months ago

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases

GlobeNewsWire - 7 months ago

Ms. Schwartz brings over 16 years of legal experience in the biopharma industry to Prevail’s leadership team Ms. Schwartz brings over 16 years of legal experience in the biopharma industry to ...

GlobeNewsWire - 8 months ago

Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup ActivitiesProgressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic Gaucher Disease and P...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor in Prevail Therapeutics Inc. (PRVL).

Zacks Investment Research - 9 months ago

Prevail Therapeutics (PRVL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 10 months ago

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patient...

Seeking Alpha - 10 months ago

Prevail Therapeutics: A Speculative Buy For Its Disease-Modifying Gene Therapies For Neurodegenerative Diseases

GlobeNewsWire - 10 months ago

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients ...

GlobeNewsWire - 11 months ago

NEW YORK, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based ...

GlobeNewsWire - 11 months ago

Orphan Drug Designation Granted for Treatment of Gaucher Disease 

GlobeNewsWire - 1 year ago

PR001 Administered to International Type 2 Gaucher Disease Patient  Via Compassionate Use Pathway

GlobeNewsWire - 1 year ago

NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based ...

24/7 Wall Street - 1 year ago

Prevail Therapeutics Inc. (NASDAQ: PRVL) shares jumped early on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation (ODD) for ...

About PRVL

Prevail Therapeutics, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and i... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2019
CEO
Dr. Asa Abeliovich M.D., Ph.D.
Employees
66
Stock Exchange
NASDAQ
Ticker Symbol
PRVL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for PRVL stock is "Hold." The 12-month stock price forecast is 23.63, which is an increase of 2.74% from the latest price.

Price Target
$23.63
(2.74% upside)
Analyst Consensus: Hold